Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.


Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.

Sethakorn N, O'Donnell PH.

BJU Int. 2016 Nov;118(5):681-691. doi: 10.1111/bju.13552. Epub 2016 Jul 7. Review.


Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, Van Hummelen P, Rustgi AK, Wong KK, Zhou Z, Tang P, Kim KM, Lee J, Bass AJ.

J Clin Invest. 2014 Dec;124(12):5145-58. doi: 10.1172/JCI75200. Epub 2014 Nov 17.


Novel molecular targets for urothelial carcinoma.

Faltas BM, Karir BS, Tagawa ST, Rosenberg JE.

Expert Opin Ther Targets. 2015 Apr;19(4):515-25. doi: 10.1517/14728222.2014.987662. Epub 2015 Jan 30. Review.


Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.

Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V, Pal SK.

Cancer. 2016 Mar 1;122(5):702-11. doi: 10.1002/cncr.29826. Epub 2015 Dec 9.


Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine.

Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS, Bolenz C.

Urol Int. 2018;100(1):122-125. doi: 10.1159/000443280. Epub 2016 Jan 19.


Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.

Ross JS, Gay LM, Nozad S, Wang K, Ali SM, Boguniewicz A, Khaira D, Johnson A, Elvin JA, Vergilio JA, Suh J, Miller VA, Stephens PJ.

Breast Cancer Res Treat. 2016 Jan;155(2):405-13. doi: 10.1007/s10549-016-3682-6. Epub 2016 Jan 13.


Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.

Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, Tabesh B, Kemper M, Batus M, Coon JS.

Genes Chromosomes Cancer. 2007 Apr;46(4):397-405.


Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D.

Cell Res. 2014 May;24(5):542-59. doi: 10.1038/cr.2014.37. Epub 2014 Mar 28.


Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma.

Gottesdiener LS, O'Connor S, Busam KJ, Won H, Solit DB, Hyman DM, Shoushtari AN.

Clin Cancer Res. 2018 Dec 1;24(23):5815-5819. doi: 10.1158/1078-0432.CCR-18-1397. Epub 2018 Aug 9.


A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ.

Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5.


Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R, Lipson D, Stephens PJ.

Oncologist. 2015 Jan;20(1):7-12. doi: 10.1634/theoncologist.2014-0234. Epub 2014 Dec 5.


HER2 as a target in invasive urothelial carcinoma.

Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J.

Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26.


ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW.

J Thorac Oncol. 2017 May;12(5):833-842. doi: 10.1016/j.jtho.2017.01.023. Epub 2017 Feb 4.


High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.

Fuchs EM, Köstler WJ, Horvat R, Hudelist G, Kubista E, Attems J, Zielinski CC, Singer CF.

Int J Cancer. 2014 Jul 1;135(1):224-31. doi: 10.1002/ijc.28660. Epub 2014 Jan 28.


Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA.

Oncologist. 2015 May;20(5):499-507. doi: 10.1634/theoncologist.2014-0378. Epub 2015 Apr 16.


Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification.

Disel U, Germain A, Yilmazel B, Abali H, Bolat FA, Yelensky R, Elvin JA, Lipson D, Chmielecki J, Wang K, Stephens PJ, Ross JS, Miller VA, Ali SM, George TJ Jr.

Oncoscience. 2015 Jul 1;2(6):581-4. eCollection 2015.


HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.

Eriksson P, Sjödahl G, Chebil G, Liedberg F, Höglund M.

Oncotarget. 2017 Jul 25;8(30):48905-48914. doi: 10.18632/oncotarget.16554.


Emerging biomarkers and targeted therapies in urothelial carcinoma.

Mendiratta P, Grivas P.

Ann Transl Med. 2018 Jun;6(12):250. doi: 10.21037/atm.2018.05.49. Review.

Supplemental Content

Support Center